Skip to main content

Sellas Life Sciences Group Inc (SLS) Stock

Sellas Life Sciences Group Inc Stock Details, Movements and Public Alerts

Stock Details

Sellas Life Sciences Group Inc (SLS), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $3.81. Over the past 52 weeks, it has ranged between $0.95 and $5.18. This places the current price at 73.6% of its 52-week high and 300.2% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 52.80, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $2.86 by 33.22%. Similarly, it is above its 200-day moving average of $2.02 by 88.61%. The MACD histogram is -0.10, indicating bearish momentum (MACD Line: 0.35, Signal Line: 0.45). There are currently 3 active alerts set for SLS by users.

52-Week Range

$5.18 - $0.95

-26.45% from high · +300.21% from low

Avg Daily Volume

12,401,635

20-day average

100-day avg: 6,317,107

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

16.42

EV/EBITDA

-1.71

EPS (TTM)

-$0.28

Price to Sales

26.90

Beta

2.27

More volatile than market

Q:How is SLS valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is SLS's risk profile compared to the market?
With a beta of 2.27, Sellas Life Sciences Group Inc is significantly more volatile than the market. For every 10% market move, this stock tends to move 23% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 16.42 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

Return on Equity

-84.30%

Return on Assets

-44.90%

Revenue Growth (YoY)

-82.50%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is SLS's business model?
Profitability metrics are not available for this stock.
Q:What are SLS's recent growth trends?
Sellas Life Sciences Group Inc's revenue declined by 82.50% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$675.2M

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

170.28M

Book Value/Share

$0.37

Asset Type

Common Stock

Q:What is SLS's market capitalization and position?
Sellas Life Sciences Group Inc has a market capitalization of $675.2M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 170.28M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does SLS's price compare to its book value?
Sellas Life Sciences Group Inc's book value per share is $0.37, while the current stock price is $3.81, resulting in a price-to-book (P/B) ratio of 10.44. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$6.83

79.27% upside potential

Analyst Recommendations

Strong Buy

1

Buy

2

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for SLS?
3 analysts cover SLS with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $6.83 implies 79.3% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on SLS?
Current analyst recommendations:1 Strong Buy, 2 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 30, 2026, 02:08 AM

Technical Indicators

RSI (14-day)

52.80

Neutral

50-Day Moving Average

$2.86

33.22% above MA-50

200-Day Moving Average

$2.02

88.61% above MA-200

MACD Line

0.35

MACD Signal

0.45

MACD Histogram

-0.10

Bearish

Q:What does SLS's RSI value tell investors?
The RSI (Relative Strength Index) for SLS is currently 52.80, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret SLS's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.35 below the signal line at 0.45, with histogram at -0.10. This bearish crossover indicates downward pressure. The 50-day MA ($2.86) is above the 200-day MA ($2.02), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jan 30, 2026, 12:33 AM

Active Alerts

Alert Condition
Golden Cross
Threshold
N/A
Created
Jan 26, 2026, 09:04 AM
Alert Condition
Volume change
Threshold
200%
Created
Jan 16, 2026, 02:21 AM
Alert Condition
Price decreases by
Threshold
8%
Created
Jan 16, 2026, 02:21 AM

Stay Ahead of the Market with Sellas Life Sciences Group Inc Alerts

Set up price alerts for Sellas Life Sciences Group Inc and get notified instantly when the price hits your target. Never miss an important price movement again.